Faster Doesn’t Mean Easier: Development Impacts of a New Biosimilar Regulatory LandscapeByKimberly SalgadoJune 3rd 2026
CPHI Americas: How FDA Instability Is Reshaping Pharmaceutical DevelopmentByZachary ZubulakeJune 2nd 2026